Bridge Therapeutics, founded with the mission to improve healthcare for millions suffering from chronic pain and opioid addiction, is a specialty pharmaceutical company. The company focuses on developing safer and more effective therapies for opioid use disorder (OUD) and chronic pain management. Their key products include BT, a novel delivery system for buprenorphine-naloxone aimed at treating OUD, and BT-, a patented drug combination designed for chronic pain in opioid-experienced patients.
Notable figures affiliated with Bridge Therapeutics include experts in pharmaceutical development and pain management. The company has achieved significant milestones, including securing U.S. patents for their innovative drug combinations. By pursuing FDA approval for their therapies, Bridge Therapeutics aims to make a substantial impact on the opioid crisis, offering new hope to patients and healthcare providers dealing with the complexities of pain and addiction.
